Severe acute respiratory syndrome vaccine - Protein Sciences

Drug Profile

Severe acute respiratory syndrome vaccine - Protein Sciences

Alternative Names: D-3252; SARS vaccine - Protein Sciences; SARS-CoV spike protein vaccine - Protein Sciences

Latest Information Update: 07 Dec 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Protein Sciences Corporation
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Severe acute respiratory syndrome

Most Recent Events

  • 07 Dec 2015 The Severe acute respiratory syndrome vaccine is still in active development
  • 11 Jan 2011 Coronavirus vaccine - Protein Sciences is available for licensing as of 11 Jan 2011. http://www.proteinsciences.com
  • 07 Jan 2011 The Severe acute respiratory syndrome vaccine is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top